Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results for the three and six months ended June 30, 2014 on Thursday, August 14, 2014. The Company will hold an investor conference call on Thursday, August 14, at 8:30 am EDT.
During the call, Jeffrey Riley, Synthetic Biologics’ Chief Executive Officer, will provide an update and review upcoming clinical milestones for the Company’s anti-infective drug pipeline to address serious infections and diseases, including the prevention of C. difficile infections, reducing the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), and the treatment of Pertussis.
Mr. Riley will also provide a reminder that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating Trimesta™, the Company’s oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), is scheduled to present additional clinical outcome data, including more detailed results on cognitive and disability measures. Dr. Voskuhl is scheduled to present at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) on September 12th in Boston. In addition, C. Evan Ballantyne, Synthetic Biologics’ Chief Financial Officer, will review the Company’s financial results for the three and six months ended June 30, 2014.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.syntheticbiologics.com.
